A Phase 3 Randomized Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (TroFuse-032) MK2870-032
